Tenderwize
Zurück zur Suche

Pharmaceutical products with active substance Tolvaptan

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Jun 29, 2027 · 308 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Tolvaptan (ATC: G04BX21 - ausgenommen Arzneimittel mit einheitlichen Wirkstärken)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

No guaranteed minimum volume or estimated value; the tender does not provide any indication of potential revenue.

Contracts may be terminated if the buyer later awards exclusive contracts for the same active substance.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for Tolvaptan (ATC G04BX21) finished medicinal products
  • Open-house model: any qualified pharmaceutical company can join
Vollständige Zusammenfassung anzeigen

This is an open-house model for non-exclusive discount agreements for Tolvaptan (ATC G04BX21) in Germany, administered by AOK Sachsen-Anhalt. It is not a typical public procurement but a transparent process for any qualified pharmaceutical company to join a discount agreement under §130a Abs. 8 SGB V. The contract duration is 24 months (01.09.2025 to 31.08.2027). No estimated value is provided. Documents are available but not analyzed. Submission is possible via platform (with QES) or postal mail.

Risiken

No guaranteed minimum volume or estimated value; the tender does not provide any indication of potential revenue.

Contracts may be terminated if the buyer later awards exclusive contracts for the same active substance.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Administrative

  • Pharmaceutical companies must request and complete the participation documents
  • Documents must be fully completed and signed
  • Submission via platform with qualified electronic signature or postal mail

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria; all qualified participants receive a contract.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Pharmaceutical products with active substance Tolvaptan

Non-exclusive discount agreements for finished medicinal products containing Tolvaptan (ATC G04BX21, excluding uniform strengths). Open-house model with no exclusivity, individual negotiations, or minimum volume. Contract duration 24 months starting 01.09.2025, ending 31.08.2027. Early termination possible if exclusive contracts are awarded.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria; all qualified participants receive a contract.

Frist

Deadline Jun 30, 2027

Vergabedetails

Veröffentlichungsdatum
13 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
457338-2025

Dokumente (1)

Ähnliche Ausschreibungen